Internal Med Medical News about Erectile Dysfunction Therapeutics Hormonal Testing

Your Unread Messages

See All

Hello, Mary O'connor
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

5. Rapid correction of low vitamin D status in nursing home residents

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Hormonal Testing and Pharmacologic Treatment of Erectile Dysfunction: A Clinical Practice Guideline From the American College of Physicians
Annals of Internal Medicine, 10/20/09

Qaseem A et al. – The American College of Physicians developed this guideline to present the available evidence on hormonal testing in and pharmacologic management of erectile dysfunction. Current pharmacologic therapies include phosphodiesterase–5 (PDE–5) inhibitors, such as sildenafil, vardenafil, tadalafil, mirodenafil, and udenafil, and hormonal treatment.

Methods

Published literature on this topic was identified by using MEDLINE (1966 to May 2007), EMBASE (1980 to week 22 of 2007), Cochrane Central Register of Controlled Trials (second quarter of 2007), PsycINFO (1985 to June 2007), AMED (1985 to June 2007), and SCOPUS (2006).
The literature search was updated by searching for articles in MEDLINE and EMBASE published between May 2007 and April 2009.
Searches were limited to English–language publications.
This guideline grades the evidence and recommendations by using the American College of Physicians' clinical practice guidelines grading system.

Results

Recommendation 1: The American College of Physicians recommends that clinicians initiate therapy with a PDE–5 inhibitor in men who seek treatment for erectile dysfunction and who do not have a contraindication to PDE–5 inhibitor use (Grade: strong recommendation; high–quality evidence).
Recommendation 2: The American College of Physicians recommends that clinicians base the choice of a specific PDE–5 inhibitor on the individual preferences of men with erectile dysfunction, including ease of use, cost of medication, and adverse effects profile (Grade: weak recommendation; low–quality evidence).
Recommendation 3: The American College of Physicians does not recommend for or against routine use of hormonal blood tests or hormonal treatment in the management of patients with erectile dysfunction (Grade: insufficient evidence to determine net benefits and harms).

<< Previous
Clinical observation on effects of scraping therapy for headache...

Next >>
Systematic Review: Charged-Particle Radiation Therapy for Cancer

Hormonal Testing and Pharmacologic Treatment of Erectile Dysfunction
Internet Source, 11/03/09 Relevance Score: 87%

Atorvastatin improves the response to sildenafil in hypercholesterolemic men with erectile dysfunction not initially responsive to sildenafil
International Journal of Impotence Research, 10/30/09 Relevance Score: 81%

Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysis
Annals of Internal Medicine, 10/23/09 Relevance Score: 81%

ED researcher gets grant to test drug
Internet Source, 10/07/09 Relevance Score: 80%

Studies show Viagra, other drugs outperform hormone treatment
Internet Source, 10/21/09 Relevance Score: 79%